In the world of growth investing, strategies that methodically find companies with quickening business momentum are highly desired. One such method is described in Louis Navellier’s The Little Book That Makes You Rich, which simplifies stock selection into eight basic rules. The aim is to find firms not only expanding, but doing so with rising profitability, favorable analyst opinion, and sound financial efficiency. This system concentrates on specific, numerical gauges of operational and earnings momentum, trying to find growth stocks early in their rising path.
XOMA Royalty Corporation (NASDAQ:XOMA) functions as a biotech royalty collector, assembling a collection of economic rights to partnered drug candidates. Its model centers on obtaining royalty interests in medicines at different development phases, from clinical tests to market sales, creating a varied income flow linked to the achievements of other companies' products.
How XOMA Fits the "Little Book" Rules
The filter built on Navellier’s eight rules selects XOMA because of its solid results across multiple important growth and momentum measures. The given information shows the company is now matching or passing the strategy's strict requirements.
- Positive Earnings Revisions & Surprises: A central idea of the strategy is that higher revisions and steady earnings beats frequently come before more price gains. XOMA displays this strongly. The average EPS estimate beat over the previous four quarters is a remarkable 623.8%, with positive surprises in all four reports. Also, analyst estimates for the next quarter's EPS have been raised by 126.3% in the last three months, showing increasing belief in short-term results.
- Quickening Sales and Earnings Growth: The strategy looks for companies where expansion is not only existing but speeding up. XOMA's revenue expansion is solid, with a 74.0% rise year-over-year and a 57.9% increase in the latest quarter versus the same quarter last year. More significantly, earnings expansion displays clear momentum. EPS expanded 157.8% quarter-over-quarter, a sharp rise from the 8.2% expansion seen in the similar period a year earlier. This good earnings momentum is a key requirement in the filter.
- Widening Profitability and Sound Cash Flow: Expansion must be profitable and produce cash. XOMA's operating margin has widened by 152.5% over the last year, showing the company is turning higher sales into earnings more effectively. At the same time, its free cash flow, the crucial funding for operations and expansion, rose by 108.5% in the past year, meeting the strategy's need for sound and bettering cash production.
- High Return on Equity (ROE): Lastly, the strategy demands effective use of shareholder capital. XOMA's ROE of 17.8% is much higher than the 10% minimum level set by the filter, showing it is creating good earnings from its equity base.
Fundamental Condition and Valuation Setting
Outside the specific filter requirements, a wider view of XOMA's fundamental picture gives setting. Based on a complete fundamental analysis report, XOMA gets an overall score of 6 out of 10. The examination notes a varied situation typical in growth-focused biotech companies.
The company's growth measures are its leading trait, with a score of 8/10. Very high past expansion in both earnings and revenue is mentioned, together with forecasts for sound future revenue growth. However, profitability and financial condition get more moderate scores (6/10 and 5/10, in that order). While current profit margins and returns on equity are very good compared to industry counterparts, the report mentions a high debt-to-free-cash-flow ratio and an Altman-Z score that indicates financial danger, which is typical for companies in capital-heavy fields like biotechnology.
Valuation shows a complicated picture, scoring 5/10. Common measures like the Price/Earnings ratio seem costly alone but are actually modest relative to the high-valuation biotechnology industry. This contrast is a standard growth-investing puzzle, the company's sound growth possibilities are being measured against its present price and balance sheet factors.
A Beginning for More Investigation
XOMA Royalty Corporation offers a strong example for the "Little Book" strategy, satisfying its multi-factor filter with clear strength in earnings revisions, surprises, and quickening growth. It shows the kind of company the system looks for, one displaying forceful operational and financial momentum.
For investors curious about finding other companies that now satisfy this growth-centered filter, the complete list of outcomes is accessible here. As with any filtering tool, these outcomes should act as a beginning for more detailed, personal examination.
,
Disclaimer: This article is for information only and does not form financial guidance, a support, or a suggestion to buy, sell, or hold any security. Investing carries danger, including the possible loss of principal. Always do your own investigation and think about your personal financial situation and danger willingness before making any investment choices.